1. Home
  2. ALBT vs BGLC Comparison

ALBT vs BGLC Comparison

Compare ALBT & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALBT
  • BGLC
  • Stock Information
  • Founded
  • ALBT 2014
  • BGLC 2017
  • Country
  • ALBT United States
  • BGLC Malaysia
  • Employees
  • ALBT N/A
  • BGLC N/A
  • Industry
  • ALBT Biotechnology: Biological Products (No Diagnostic Substances)
  • BGLC Medical Specialities
  • Sector
  • ALBT Health Care
  • BGLC Health Care
  • Exchange
  • ALBT Nasdaq
  • BGLC Nasdaq
  • Market Cap
  • ALBT 2.9M
  • BGLC 7.6M
  • IPO Year
  • ALBT N/A
  • BGLC N/A
  • Fundamental
  • Price
  • ALBT $0.20
  • BGLC $0.37
  • Analyst Decision
  • ALBT
  • BGLC
  • Analyst Count
  • ALBT 0
  • BGLC 0
  • Target Price
  • ALBT N/A
  • BGLC N/A
  • AVG Volume (30 Days)
  • ALBT 633.7K
  • BGLC 117.9K
  • Earning Date
  • ALBT 11-12-2024
  • BGLC 11-20-2024
  • Dividend Yield
  • ALBT N/A
  • BGLC N/A
  • EPS Growth
  • ALBT N/A
  • BGLC N/A
  • EPS
  • ALBT N/A
  • BGLC N/A
  • Revenue
  • ALBT N/A
  • BGLC $9,183,168.00
  • Revenue This Year
  • ALBT N/A
  • BGLC N/A
  • Revenue Next Year
  • ALBT N/A
  • BGLC N/A
  • P/E Ratio
  • ALBT N/A
  • BGLC N/A
  • Revenue Growth
  • ALBT N/A
  • BGLC N/A
  • 52 Week Low
  • ALBT $0.16
  • BGLC $0.31
  • 52 Week High
  • ALBT $1.44
  • BGLC $3.39
  • Technical
  • Relative Strength Index (RSI)
  • ALBT 43.14
  • BGLC 32.80
  • Support Level
  • ALBT $0.16
  • BGLC $0.38
  • Resistance Level
  • ALBT $0.22
  • BGLC $0.49
  • Average True Range (ATR)
  • ALBT 0.03
  • BGLC 0.02
  • MACD
  • ALBT 0.00
  • BGLC -0.01
  • Stochastic Oscillator
  • ALBT 27.54
  • BGLC 5.94

About ALBT Avalon GloboCare Corp.

Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.

Share on Social Networks: